Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenues:
Product sales	$ 7,795	$ 2,102
Product royalty revenues	1,661	934
Research and development reimbursements	22	4
Contract revenues	20,000
Total Revenues:	29,478	3,040
Cost of sales	5,645	2,550
Expenses:
Research and development	2,671	5,377
Selling, general and administrative	13,259	13,055
Total Expenses:	15,930	18,432
Income (loss) from operations	7,903	(17,942)
Interest expense, net	(2,886)	(778)
Other expense, net		(13)
Bargain purchase gain	27,336
Income (loss)	32,353	(18,733)
Income tax benefit	15,972
Net income (loss) attributable to common stockholders	$ 48,325	$ (18,733)
Basic
Basic income (loss) per share:	$ 0.89	$ (0.36)
Weighted average common stock shares outstanding:	54,519,574	52,230,648
Diluted
Diluted income (loss) per share:	$ 0.87	$ (0.36)
Diluted weighted average common stock shares outstanding:	55,431,628	52,230,648